These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 26146634)

  • 1. Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
    Silva Júnior WS; Godoy-Matos AF; Kraemer-Aguiar LG
    Biomed Res Int; 2015; 2015():816164. PubMed ID: 26146634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM).
    Mora-Rodríguez JM; Sánchez BG; Bort A; Díaz-Yuste A; Ballester-González R; Arrieta F; Sebastián-Martín A; Díaz-Laviada I
    Life Sci; 2024 Jan; 336():122292. PubMed ID: 38030058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.
    Zhong J; Maiseyeu A; Davis SN; Rajagopalan S
    Circ Res; 2015 Apr; 116(8):1491-504. PubMed ID: 25858071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism.
    Mulvihill EE
    Peptides; 2018 Feb; 100():158-164. PubMed ID: 29412815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The regulatory role of DPP4 in atherosclerotic disease.
    Duan L; Rao X; Xia C; Rajagopalan S; Zhong J
    Cardiovasc Diabetol; 2017 Jun; 16(1):76. PubMed ID: 28619058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease.
    Remm F; Franz WM; Brenner C
    Eur Heart J Cardiovasc Pharmacother; 2016 Jul; 2(3):185-93. PubMed ID: 27533760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases.
    Xie W; Song X; Liu Z
    Vascul Pharmacol; 2018 Oct; 109():17-26. PubMed ID: 29879463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease.
    Zhong J; Rao X; Rajagopalan S
    Atherosclerosis; 2013 Feb; 226(2):305-14. PubMed ID: 23083681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The protective role of DPP4 inhibitors in atherosclerosis.
    Liu H; Guo L; Xing J; Li P; Sang H; Hu X; Du Y; Zhao L; Song R; Gu H
    Eur J Pharmacol; 2020 May; 875():173037. PubMed ID: 32097656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretin-based therapies, glucometabolic health and endovascular inflammation.
    Rizzo M; Nikolic D; Banach M; Patti AM; Montalto G; Rizvi AA
    Curr Pharm Des; 2014; 20(31):4953-60. PubMed ID: 24320037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Dipeptidyl Peptidase-4 (DPP4) on Mesenchymal Stem-Cell (MSC) Biology: Implications for Regenerative Medicine - Review.
    Torrecillas-Baena B; Gálvez-Moreno MÁ; Quesada-Gómez JM; Dorado G; Casado-Díaz A
    Stem Cell Rev Rep; 2022 Jan; 18(1):56-76. PubMed ID: 34677817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of neurodegeration in type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors.
    Matteucci E; Giampietro O
    Curr Med Chem; 2015; 22(13):1573-81. PubMed ID: 25723507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms.
    Zakaria EM; Tawfeek WM; Hassanin MH; Hassaballah MY
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Nov; 395(11):1357-1372. PubMed ID: 35945358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protection.
    Avogaro A; de Kreutzenberg S; Fadini G
    Curr Pharm Des; 2014; 20(14):2387-94. PubMed ID: 23844811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
    Balakumar P; Dhanaraj SA
    Cell Signal; 2013 Sep; 25(9):1799-803. PubMed ID: 23707531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DPP-4 inhibitors in the treatment of type 2 diabetes.
    Duez H; Cariou B; Staels B
    Biochem Pharmacol; 2012 Apr; 83(7):823-32. PubMed ID: 22172989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.
    Ahmed HA; May DW; Fagan SC; Segar L
    Pharmacotherapy; 2015 Mar; 35(3):277-97. PubMed ID: 25754657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.
    Klemann C; Wagner L; Stephan M; von Hörsten S
    Clin Exp Immunol; 2016 Jul; 185(1):1-21. PubMed ID: 26919392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Degradation of Incretins and Modulation of Blood Glucose Levels by Periodontopathic Bacterial Dipeptidyl Peptidase 4.
    Ohara-Nemoto Y; Nakasato M; Shimoyama Y; Baba TT; Kobayakawa T; Ono T; Yaegashi T; Kimura S; Nemoto TK
    Infect Immun; 2017 Sep; 85(9):. PubMed ID: 28630069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
    Koska J; Sands M; Burciu C; Reaven P
    Diab Vasc Dis Res; 2015 May; 12(3):154-63. PubMed ID: 25852133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.